IE
JSPR icon

Israel Englander’s Jasper Therapeutics JSPR Stock Holding History

Israel Englander’s Portfolio JSPR Stock Details JSPR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-65,000
Closed -$1.39M – 6148
2024
Q4 		$1.39M Buy
+65,000
New +$1.35M ﹤0.01% 3925

Other funds holding JSPR

VCIM
Velan Capital Investment Management Alpharetta, Georgia $164M AUM 542.31% 1-Year Est. Return
ACA
Acorn Capital Advisors New York $366M AUM 474.6% 1-Year Est. Return
KCM
Kingdon Capital Management New York $976M AUM 66.76% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
RSCM
Rock Springs Capital Management Baltimore, Maryland $2.05B AUM 161.37% 1-Year Est. Return
CG
Carlyle Group Washington, District of Columbia $10B AUM 10.61% 1-Year Est. Return
GCP
GSA Capital Partners London, United Kingdom $1.59B AUM 39.81% 1-Year Est. Return
LPC
Lion Point Capital New York $20.9M AUM 195.52% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Israel Englander's JSPR Position: Q2 2026 in Review

Israel Englander reduced its Jasper Therapeutics (JSPR) stake by 70% in Q2 2026, selling an estimated $846K and leaving 486,933 shares worth $205K. The position accounts for ﹤0.01% of the portfolio, ranked #5306.

Israel Englander first reported a position in JSPR in Q1 2021 and has held it in 16 quarters since. The position peaked at $3.27M in Q1 2024. 45 funds tracked by Wall St. Rank hold JSPR as of Q2 2026.

  • Israel Englander held 486,933 shares of Jasper Therapeutics worth $205K as of Q2 2026.
  • Israel Englander sold 1,130,598 Jasper Therapeutics shares in Q2 2026, an estimated $846K.
  • Jasper Therapeutics made up ﹤0.01% of Israel Englander's portfolio in Q2 2026, its #5306 holding.
  • Israel Englander first reported a position in Jasper Therapeutics in Q1 2021 and has held it in 16 quarters since.
  • Israel Englander's Jasper Therapeutics position peaked at $3.27M in Q1 2024.
  • 45 funds tracked by Wall St. Rank held Jasper Therapeutics as of Q2 2026.

Based on Millennium Management's 13F filing for Q2 2026, filed 14 Aug 2026.